Like many other Seeking Alpha contributors, I'm a huge fan of companies with management with proven track records in creating shareholder value. Unquestionably, Shai Novik, founder and president of Prolor Biotech has done so.
Last year I wrote that Prolor Biotech (PBTH) was a prime candidate for a buyout, based on its valuation, clinical assets, and investor Philip Frost's involvement with both Prolor and Teva (TEVA). Although Teva turned out not to be the buyer, my original thesis played out almost exactly: Prolor was acquired by OPKO Health (OPK) earlier this year. (Frost is also the CEO and Chairman of OPKO.) For readers who bought Prolor when I wrote the article, the...
Only subscribers can access this article, which is part of the PRO research library covering 3,801 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: